Key Highlights
- Cue Biopharma (NASDAQ:CUE) was trading down 51.45% at USD 6.85 on Tuesday, November 17, 2026, per published market data. Calculated arithmetic implies a prior close near USD 14.11, which is not a verified quote.
- The Quarterly Report for the period ended September 30, 2026 shows cash of USD 57.9 million, up from USD 27.1 million at December 31, 2025, and a third-quarter net loss of USD 50.0 million against USD 7.4 million a year earlier.
- The nine-month net loss was USD 208.3 million. Per the 10-Q, it includes a non-cash loss of about USD 90.0 million on issuing liability-classified warrants and USD 59.4 million of stock-based compensation.
- A 1-for-30 reverse split took effect on April 23, 2026, cutting shares from about 97.7 million to about 3.3 million. The 10-Q cover reports 8,359,523 shares outstanding as of November 13, 2026.
A 51.45% Drop With No Dated Company Announcement
Cue Biopharma (NASDAQ:CUE) was trading down 51.45% at USD 6.85 on Tuesday, November 17, 2026, in published market data. No company press release, trial update or financing notice explaining the drop was found for November 14 to November 17, so the cause is not confirmed. Dividing USD 6.85 by 0.4855 gives a prior close of about USD 14.11, which is calculated and should not be read as a verified quote. On a small share count, a move of this size can reflect a few trades, wide spreads and quotes that reverse.
What the September 30 Quarterly Report Shows
The 10-Q for the period ended September 30, 2026 reports cash and equivalents of USD 57.9 million, against USD 27.1 million at December 31, 2025. Collaboration Revenue was USD 0.1 million in the quarter, down from USD 2.1 million a year earlier, while nine-month revenue rose to USD 13.7 million from USD 5.5 million. The third-quarter net loss reached USD 50.0 million, compared with USD 7.4 million, and the nine-month loss was USD 208.3 million. Per the filing, the nine-month figure includes a non-cash loss of about USD 90.0 million on issuing liability-classified warrants and USD 59.4 million of stock-based compensation, so cash burn is not the same as the headline loss.
Reverse Split, Dilution and the CUE-401 Phase 1 Risk
The company approved a 1-for-30 reverse split at its April 13, 2026 annual meeting and made it effective on April 23, 2026, in part to regain compliance with the Nasdaq minimum bid price requirement. That cut shares from about 97.7 million to about 3.3 million, and the 10-Q cover reports 8,359,523 shares on November 13, 2026, up from 7,753,995 at September 30. On December 19, 2025, the company priced a USD 10 million offering of 35,714,286 shares or pre-funded warrants with warrants for 17,857,143 shares. Dosing in a Phase 1 trial of CUE-401, its autoimmune candidate, began in October 2026, and early-stage data carry high failure risk. Management says cash should fund operations for at least twelve months, but future viability depends on raising more capital.
Where Things Stand
No company announcement explaining the 51.45% drop was found, so it is best read as unexplained for now. Cue Biopharma (NASDAQ:CUE) enters the session with more cash than at year-end, a lead autoimmune candidate in a Phase 1 trial and a funding outlook that depends on future capital. Against that, the quarterly loss widened sharply, partly because of non-cash Warrant and Stock Compensation charges, and the share count has grown since the reverse split. Items to watch are any company filing or release about the move, the 10-Q filing date, early CUE-401 data and any new financing. A quoted move on a low share count can reverse once trading Volume settles.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...